12:00 AM
Jan 19, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Afinitor everolimus: Phase II data

In an open-label, Japanese Phase II trial in 54 Asian patients with advanced gastric cancer, 10 mg daily Afinitor had a 55% disease control rate at week 8 and resulted in tumor shrinkage in 45% of patients. The median PFS was 83...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >